股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年3月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國神威藥業集團有限公司 呈交日期: 2026年4月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02877 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.1 | HKD | | 500,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 5,000,000,000 | HKD | | 0.1 | HKD | | 500,000,000 | 本月底法定/註冊 ...

Group 1 - The company has successfully won bids for eight major products in the national traditional Chinese medicine procurement alliance, covering treatment areas such as cardiovascular diseases, respiratory diseases, and digestive system diseases, which are commonly used in clinical applications and included in medical insurance and essential drug lists [2] - The successful bidding aligns the products with DRG/DIP payment requirements, providing better medication options for more patients and enhancing future market demand, market coverage, and sales potential for the company's products [2] - The traditional Chinese medicine granule industry is entering a period of deep adjustment characterized by declining sales, with the company's sales revenue for traditional Chinese medicine granules decreasing by 14.4% due to multiple policy impacts [2] Group 2 - For the fiscal year ending December 31, 2025, the company reported a revenue of RMB 3.135 billion, a decrease of 17.0% compared to the previous year, with a gross margin of 72.3%, down from 75.0% last year [3] - The annual profit increased by 13.1% to RMB 950 million, with earnings per share at RMB 1.26, and the company declared an interim dividend of RMB 0.43 per share for 2026 [3]

Core Viewpoint - Shenwei Pharmaceutical (02877) reported its annual performance, showing a revenue decline but an increase in annual profit, leading to a significant stock price increase of over 8% following the announcement [1] Financial Performance - The company's total revenue for the year was 3.135 billion RMB, representing a year-on-year decrease of 17.0% [1] - Annual profit reached 950 million RMB, which is a year-on-year increase of 13.1% [1] - Earnings per share were reported at 1.26 RMB [1] Dividend Information - The company declared an interim dividend of 0.43 RMB per share for the first half of 2026, along with a second interim dividend of 0.11 RMB per share for the fiscal year 2025 [1] - The total dividend for the fiscal year 2025 amounts to 0.54 RMB per share, with a payout ratio of 42.9% [1] Product Procurement and Market Impact - In 2025, the company secured bids for eight key products in the national Chinese medicine procurement alliance, covering treatment areas such as cardiovascular, respiratory, and digestive diseases [1] - The successful procurement aligns with DRG/DIP payment requirements, enhancing the availability of quality medications at competitive prices for patients [1] - This procurement is expected to boost future market demand, market coverage, and sales potential for the company's products [1]

Group 1: Company Performance - The company reported a total revenue of RMB 3.135 billion for the fiscal year ending December 31, 2025, representing a 17.0% decrease compared to the previous year [1][4] - The gross profit margin decreased to 72.3% from 75.0% in the previous year [1][4] - The annual profit increased by 13.1% to RMB 950 million, with earnings per share at RMB 1.26 [1][4] - The company declared an interim dividend of RMB 0.43 per share for 2026 [1][4] Group 2: Product and Market Developments - In 2025, the company successfully won bids for eight key products in the national Chinese medicine procurement alliance, covering treatment areas such as cardiovascular, respiratory, and digestive diseases [1][4] - The successful bids align with DRG/DIP payment requirements, enhancing the availability of quality medications at competitive prices for patients, which is expected to boost future market demand and sales [1][4] Group 3: Industry Trends - The traditional Chinese medicine granule industry has entered a period of deep adjustment, characterized by declining sales due to the implementation of national standards, normalization of provincial procurement, and ongoing healthcare cost control [2][5] - The company's sales revenue from traditional Chinese medicine granules decreased by 14.4% during the year [2][5] - The sales team is focused on expanding into target provinces, controlling costs, and enhancing regional and product competitiveness, with expectations of regaining growth as the industry stabilizes [2][5]

Group 1 - The core viewpoint of the articles highlights the financial performance of Shenwei Pharmaceutical (02877), reporting a net profit of RMB 950 million, which represents a year-on-year increase of 13.1% despite a decline in revenue [1] - The company's total revenue for the fiscal year ending December 31, 2025, was RMB 3.135 billion, a decrease of 17.0% compared to the previous year, with a gross margin of 72.3%, down from 75.0% last year [1] - The company declared an interim dividend of RMB 0.43 per share for 2026, with earnings per share reported at RMB 1.26 [1] Group 2 - The traditional Chinese medicine granule industry is experiencing a significant adjustment period characterized by declining sales due to multiple policy impacts, including the implementation of national standards and the normalization of provincial centralized procurement [2] - The sales revenue of the company's traditional Chinese medicine granules decreased by 14.4% during the year, reflecting the overall industry trend [2] - The company is actively working to expand its sales team, control costs, and enhance regional and product competitiveness, with expectations of regaining growth as the industry landscape stabilizes [2]

EF001 免責聲明 第 1 頁 共 2 頁 v 1.1.1 EF001 發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 於本公告日期，執行董事包括李振江先生、信蘊霞女士及李惠民先生；非執行董事為周文成先生；而獨立非執行董事包括廖舜輝先 生、姚逸安先生及王桂華女士。 第 2 頁 共 2 頁 v 1.1.1 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 中國神威藥業集團有限公司 | | 股份代號 | 02877 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至二零二六年十二月三十一日止年度第一次中期股息 | | 公告日期 | 2026年3月27日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 其他 ...

Core Viewpoint - Shenwei Pharmaceutical (02877.HK) reported a significant decline in revenue and gross profit for the fiscal year 2025, reflecting challenges in the traditional Chinese medicine industry due to various external pressures [1] Company Performance - Revenue for the year was RMB 3.135 billion, a decrease of 17.0% compared to the previous year [1] - Gross profit amounted to RMB 2.266 billion, down 20% year-on-year [1] - The profit attributable to shareholders increased by 13.1% to RMB 950 million [1] - Basic earnings per share were RMB 1.26, with a proposed interim dividend of RMB 0.43 per share for 2026 [1] Industry Context - The traditional Chinese medicine industry is undergoing a deep adjustment and value reconstruction period due to five major factors: medical insurance cost control, centralized procurement price reductions, shrinking demand, consumer downgrade, and rising production costs [1] - Overall sales in the industry have declined, with most product revenues experiencing significant decreases during the year [1]

Financial Performance - The company's revenue for the year ended December 31, 2025, was RMB 3,135,419,000, a decrease of 17.0% compared to the previous year[3] - Net profit increased by 13.1% to RMB 949,948,000, with earnings per share at RMB 1.26[3] - The overall sales of the group in 2025 decreased significantly, with total sales amounting to RMB 3,135,419,000, representing a year-on-year decline of 17.0%[12] - Gross profit for the same period was RMB 2,266,207,000, down from RMB 2,831,749,000, reflecting a gross margin decline[59] - The group reported a net exchange gain of approximately RMB 31,164,000 from currency fluctuations, compared to a net loss of RMB 55,440,000 in the previous year[45] - The effective tax rate for the group in 2025 was 25.2%, a decrease from 26.7% in 2024[51] - The group incurred a tax expense of RMB 319,318,000 in 2025, compared to RMB 305,669,000 in 2024, reflecting a slight increase[79] - The pre-tax profit for the year ending December 31, 2025, is estimated at RMB 1,269,266,000, representing a 10.8% increase from RMB 1,145,721,000 in 2024[81] Sales and Market Trends - The gross profit margin declined to 72.3% from 75.0% in the previous year, primarily due to rising raw material costs and the impact of centralized procurement on drug prices[10] - Sales revenue from traditional Chinese medicine formula granules decreased by 14.4% during the year, reflecting the overall market adjustment[5] - The overall pharmaceutical market in China experienced a decline in sales and gross margins, impacting the company's performance in 2025[10] - Injection products saw a total sales decrease of 19.8%, primarily due to significant declines in sales of Qingkailing and Shenmai injections by 37.3% and 26.3%, respectively[13] - The sales of traditional Chinese medicine formula granules decreased by 14.4% to RMB 933,657,000, accounting for 29.8% of total sales[18] - The overall sales of basic drugs listed in the national essential drug list fell by 24.5% to RMB 1,017,406,000, representing 32.4% of the group's total sales[15] - Prescription drugs and OTC drugs accounted for approximately 89.1% and 10.9% of total sales, respectively, with prescription drugs declining by 16.8% and OTC drugs by 19.0%[17] Research and Development - The company is focusing on innovation and efficiency improvements, with over 100 projects in the research and development pipeline for classic formulas and innovative traditional Chinese medicine[7] - The group invested 3.3% of its total sales revenue in R&D during the year, focusing on modern traditional Chinese medicine in areas such as cardiovascular diseases, pediatrics, orthopedics, gynecology, and geriatric diseases[31] - The group is conducting clinical trials for multiple research projects, with the innovative drug "Q-B-Q-F Concentrated Pill" currently in Phase III trials, while "Sailuotong Capsules" and "JC Capsules" have completed Phase III trials and are in the process of applying for production licenses[30] - The company has completed the III phase clinical trials for the self-developed JC capsule for upper respiratory infections, with a production license application submitted and accepted, expected to be obtained by early 2026[23] Strategic Initiatives - The company aims to enhance its core competitiveness through digital transformation and refined management as part of its strategic goals for the 14th Five-Year Plan[7] - The company is actively implementing a digital transformation strategy, integrating AI technology into business operations, and successfully applying it in the centralized procurement agreement signing process[20] - The group is focusing on expanding oral formulations as a key development strategy moving forward[12] - The company has successfully won bids for eight major products in the national centralized procurement alliance, covering key therapeutic areas such as cardiovascular, respiratory, and digestive diseases[5] Dividends and Financial Management - The board declared an interim dividend of RMB 0.43 per share for 2026, with a total dividend related to the 2025 fiscal year amounting to RMB 0.54 per share, representing a payout ratio of 42.9%[11] - The company declared a first interim dividend of RMB 0.43 per share for 2026, totaling RMB 324,822,000, an increase from RMB 271,944,000 in 2024[83] - The company's cash and cash equivalents increased to RMB 7,189,047,000 from RMB 6,140,153,000, indicating improved liquidity[60] - The total employee costs, including directors' remuneration, amounted to RMB 337,885,000 in 2025, a decrease of 13.8% from RMB 391,824,000 in 2024[76] Compliance and Governance - The company has complied with the Corporate Governance Code, except for a deviation from the code provision C.2.1 regarding the separation of roles between the chairman and the CEO[94] - The roles of the chairman and the president are clearly defined, with the same individual, Mr. Li Zhenjiang, serving as both chairman and president, which the board believes is beneficial for executing the company's business strategy[95] - The audit committee has reviewed the audited financial performance of the group for the year ending December 31, 2025[97] - Deloitte Touche Tohmatsu has verified the financial figures in the preliminary announcement against the audited consolidated financial statements approved by the board on March 27, 2026[98]

Group 1 - The company, Shenwei Pharmaceutical (02877.HK), announced a board meeting scheduled for March 27, 2026, to be held at 31/F, Central Plaza, 18 Harbour Road, Wanchai, Hong Kong [1] - The purpose of the board meeting includes the approval of the annual results for the company and its subsidiaries for the year ending December 31, 2025, as well as the consideration of dividend declaration [1]

( 在開曼群島註冊成立之有限責任公司 ) ( 股份代號： 2877) 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致 的任何損失承擔任何責任。 CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED 中國神威藥業集團有限公司 承董事會命 中國神威藥業集團有限公司 主席 李振江 香港，二零二六年三月十七日 於本公告刊發日期，執行董事包括李振江先生、信蘊霞女士及李惠民先生。非執行董事為周 文成先生。獨立非執行董事包括廖舜輝先生、姚逸安先生及王桂華女士。 董事會會議通告 中國神威藥業集團有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將於 二零二六年三月二十七日星期五於香港灣仔港灣道18號中環廣場31樓3109室舉行董事 會會議，藉以（其中包括）批准發佈本公司及其附屬公司截至二零二五年十二月三十 一日止年度業績及考慮宣派股息。 ...